Everyone needs a backup plan, including one of the biggest biotech companies in town. So when Biogen earlier this year gave up on turning a profit from its beleaguered Alzheimer’s drug, Aduhelm, the Cambridge company moved its chips to another experimental Alzheimer’s treatment.
The new drug, called lecanemab, could be safer and provide more obvious benefits than its controversial predecessor, and Biogen expects results from an advanced clinical trial this fall. And, as was once said of Aduhelm, the outcome of the lecanemab trial will be crucial for Biogen’s future.
Create a display name to comment
This name will appear with your comment